CJC-1295 (no DAC)

Dosing and concentration

Experimental dose information: 100 micrograms under the skin, one to three times daily, is not an established prescription for every preparation labelled no DAC. Confirm the exact compound and prescribed schedule.

A reliable record identifies exact compound, amount in micrograms, concentration, route and actual administration time. For blends, record each ingredient separately even if both are delivered in one volume.

As an arithmetic example, a documented 2 mg in 2 mL equals 1,000 micrograms/mL. If a blend also contains another 2 mg ingredient in that same volume, each ingredient has its own 1,000 micrograms/mL concentration. The total blend concentration is not the concentration of either peptide alone.

Preparation and reconstitution

Start with the full identity. “CJC” without a DAC designation or verified sequence is an inadequate basis for transferring preparation or dosing directions.

A lyophilised vial is freeze-dried. Reconstitution requires the specified diluent and volume for the actual preparation. Bacteriostatic water contains a preservative, commonly benzyl alcohol, but that does not make it suitable for every peptide or establish a usable period after mixing.

For a prescribed injectable preparation, use the supplied instructions, a clean preparation area and sterile single-use equipment. Keep the peptide vial, diluent and final concentration clearly labelled. Do not substitute a different solvent to improve appearance, and do not assume that adding more water makes an uncertain preparation safe.

Check whether instructions specify the volume added or the final volume. Calculations should use the documented final concentration, especially when a blend or different vial strength is involved. A clear solution demonstrates dissolution, not verified sterility or identity.

Administration

Injection under the skin refers to the fat beneath the skin. It is not an instruction to inject into a sore tendon, joint or muscle. These peptides act through hormone signalling; a location near a painful area does not establish a targeted repair effect.

A prescribed product should come with teaching on site selection and the particular needle or device. Rotate appropriate sites and avoid bruised, irritated or infected skin. Use new sterile equipment for every administration and place used sharps in an appropriate container.

Record actual times rather than only planned times. Do not compress several missed administrations into a short period to make a schedule look complete. If the preparation changes, recheck concentration before reusing any saved syringe-volume entry.

Routes and bioavailability

Oral delivery exposes the peptide to digestive enzymes and the gut barrier. Subcutaneous delivery bypasses that first stage, but a higher or more predictable bloodstream exposure still has to be demonstrated for the actual product.

Sublingual and nasal products are separate formulations, not alternative names for an injection. Their absorption cannot be assumed from a subcutaneous amount.

CJC without DAC targets hormone signalling, not the gut surface. Low oral absorption is not a local-gut benefit. An oral product cannot be treated as equivalent to an injection.

Half-life

This is a short-acting peptide. The often-quoted 30-minute estimate is not a dependable value for every preparation. It does not determine how often you should inject.

Storage

Use the actual preparation's labelled storage and discard instructions. Keep separate dates for vial expiry, preparation and first opening. A generic “refrigerate for 30 days” statement is insufficient for an unknown concentration or blend.

Protect the vial from inappropriate heat and light, and do not freeze unless specifically directed. A long trip in a warm bag is a storage event worth recording, even if the liquid still looks normal.

Do not pool leftovers, top up an older vial or transfer material to an unlabelled container. Retain the batch and concentration so a future symptom or dosing question can be traced to the correct preparation.

Contraindications and side effects

Growth-hormone stimulation can be relevant to glucose control, fluid retention and conditions affected by growth signalling. Active cancer, pituitary disease, diabetes, significant swelling or unexplained headaches warrant medical review before considering use.

Potential problems include local injection reactions, flushing, headache, tingling, joint discomfort and metabolic changes. Short acting does not mean free of these concerns. A blend can make it difficult to tell which ingredient caused a reaction.

Do not start a self-directed course during pregnancy, breastfeeding or childhood. Review existing hormone treatments and diabetes medicines. Breathing difficulty, severe allergy or a severe headache with vision changes needs urgent assessment.

Tracking progress and everyday questions

Keep exact identity visible in the plan. Record sleep, recovery, training and unwanted effects separately. A change in IGF-1, if measured by a clinician, should be interpreted with age, laboratory range and the timing of exposure.

Is no DAC the same as sermorelin? No; the commonly intended modified GRF has sequence changes. Can a with-DAC schedule be used? No. Does pairing with ipamorelin prove better results? It explains a biological rationale, but it does not establish the clinical benefit of a particular blend.